| SEGMENT REPORTING |
8
— SEGMENT REPORTING
The
Company has one reportable operating segment relating to drug development for addiction and related disorders. When evaluating the Company’s
financial performance, the CODM reviews total operating expenses for the operating segment excluding discontinued operations and equity
method investments. The CODM makes decisions using this information on a company-wide basis.
Significant
segment expenses, as provided to the CODM, are presented below:
| | |
For the Three Months Ended | | |
For the Six Months Ended | |
| | |
June 30, | | |
June 30, | |
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| Operating Expenses: | |
| | | |
| | | |
| | | |
| | |
| Segment research and development expenses | |
$ | 732,315 | | |
$ | 1,012,522 | | |
$ | 1,479,205 | | |
$ | 1,466,800 | |
| Segment general and administrative expenses | |
| 1,150,397 | | |
| 1,274,708 | | |
| 2,670,799 | | |
| 2,665,452 | |
| Total Operating Expenses | |
| 1,882,712 | | |
| 2,287,230 | | |
| 4,150,004 | | |
| 4,132,252 | |
| | |
| | | |
| | | |
| | | |
| | |
| Loss From Operations | |
| (1,882,712 | ) | |
| (2,287,230 | ) | |
| (4,150,004 | ) | |
| (4,132,252 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Other Income (Expense) | |
| | | |
| | | |
| | | |
| | |
| Interest income | |
| 23,747 | | |
| 51,404 | | |
| 59,093 | | |
| 74,207 | |
| Inducement expense | |
| — | | |
| — | | |
| — | | |
| (4,464,427 | ) |
| Loss on equity method investment | |
| (98,730 | ) | |
| (222,472 | ) | |
| (261,820 | ) | |
| (412,343 | ) |
| Other income (expenses) | |
| (861 | ) | |
| — | | |
| 165,374 | | |
| (43 | ) |
| Total other income (expense) | |
| (75,844 | ) | |
| (171,068 | ) | |
| (37,353 | ) | |
| (4,802,606 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net Loss | |
$ | (1,958,556 | ) | |
$ | (2,458,298 | ) | |
$ | (4,187,357 | ) | |
$ | (8,934,858 | ) |
|